GAMMA Investing LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GAMMA Investing LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 907 shares of the biopharmaceutical company’s stock after selling 529 shares during the period. GAMMA Investing LLC’s holdings in Regeneron Pharmaceuticals were worth $646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Principal Financial Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares in the last quarter. DGS Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 13.8% in the third quarter. DGS Capital Management LLC now owns 429 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 52 shares in the last quarter. Oddo BHF Asset Management Sas purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,598,000. American Trust bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $600,000. Finally, Synovus Financial Corp lifted its holdings in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock worth $1,977,000 after purchasing an additional 61 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.4 %

NASDAQ:REGN opened at $718.15 on Friday. The firm has a market capitalization of $78.92 billion, a P/E ratio of 17.77, a P/E/G ratio of 2.19 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $768.44 and a 200 day moving average of $973.89. Regeneron Pharmaceuticals, Inc. has a 52 week low of $693.00 and a 52 week high of $1,211.20.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on REGN. Citigroup began coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Barclays reduced their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,052.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.